Related Experiment Video
Updated: Jun 1, 2025
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
2.8K
New Insights on Childhood Lupus Nephritis
Rodrigo Marchi-Silva1,2, Bruna Martins De Aquino1,2, Ana Carolina Londe1,2
1Medical Pathophysiology Graduate Program, School of Medical Science, Universidade Estadual de Campinas, Campinas, Brazil.
International Journal of Nephrology and Renovascular Disease
|January 20, 2025
Summary
Childhood-onset systemic lupus erythematosus (cSLE) frequently involves lupus nephritis, a severe kidney complication. Advances in diagnosis and biomarkers offer hope for improved management and outcomes in pediatric lupus patients.
Area of Science:
- Pediatric Nephrology
- Rheumatology
- Immunology
Background:
- Systemic lupus erythematosus (SLE) onset in childhood (cSLE) affects approximately 20% of patients.
- Lupus nephritis is more prevalent and severe in cSLE compared to adult-onset SLE, leading to increased morbidity and mortality.
- Early diagnosis and effective management are critical for improving long-term outcomes in cSLE patients with kidney involvement.
Purpose of the Study:
- To review the current understanding of lupus nephritis in cSLE.
- To discuss recent advancements in pathogenesis, diagnosis, biomarkers, and management strategies.
- To highlight the need for improved non-invasive biomarkers for better disease monitoring and treatment development.
Main Methods:
- Comprehensive literature review of lupus nephritis in cSLE.
- Analysis of diagnostic criteria and clinical presentation in pediatric patients.
- Evaluation of recent developments in renal biopsy scoring and non-invasive biomarker research (PubMed search July-December 2024).
Main Results:
- Lupus nephritis is diagnosed in 93% of cSLE patients within two years of disease onset.
- Nephrotic proteinuria and hypertension are common at diagnosis; Class III/IV nephritis occurs in over 50% of biopsies.
- Recent progress includes refined nephritis scoring and development of non-invasive biomarkers for disease activity and damage.
Conclusions:
- Lupus nephritis presents aggressively in cSLE, necessitating prompt diagnosis and management.
- Advancements in diagnostic tools and biomarkers are crucial for stratifying risk and guiding therapy.
- Further development and validation of non-invasive biomarkers are anticipated to facilitate multicenter studies and novel treatment strategies for cSLE nephritis.
